Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 6, June, p. 781–786

doi: 10.17219/acem/68975

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Validation of the Portuguese version of Addenbrooke’s Cognitive Examination III in mild cognitive impairment and dementia

Bruno Peixoto1,2,A,B,C,D,E,F, Milene Machado3,B,C,E,F, Patricia Rocha3,B,C,E,F, Carla Macedo3,B,C,E,F, António Machado3,B,C,E,F, Élia Baeta4,A,C,D,E,F, Gerly Gonçalves5,B,C,E,F, Paulo Pimentel6,A,B,C,E,F, Emanuela Lopes5,A,C,E,F, Luis Monteiro1,A,C,E,F

1 University Institute of Health Sciences, Advanced Polytechnic and University Cooperative (CESPU), Gandra, Portugal

2 NeuroGen – Center for Health Technology and Services Research (CINTESIS), Porto, Portugal

3 Institute of Research and Advanced Training in Health Sciences and Technologies, Advanced Polytechnic and University Cooperative (CESPU), Gandra, Portugal

4 The Alto Minho Hospital Center, Viana do Castelo, Portugal

5 The Alto Ave Hospital Center, Guimarăes, Portugal

6 The Trás-os-Montes and Alto Duoro Hospital Center, Vila Real, Portugal

Abstract

Background. Cognitive assessment is central to the diagnosis of cognitive impairment and dementia, and it should be performed in all patients in the early stages of the disease. Recently, the 3rd version of Addenbrooke’s Cognitive Examination (ACE-III) has been developed in order to improve the previous versions.
Objectives. The aim of this study was to determine the psychometric properties of the Portuguese version of ACE-III, namely: reliability and discriminative validity (sensitivity and specificity) in the identification of mild cognitive impairment (MCI) and dementia, in comparison to other neuropsychological screening tests, as well as to establish its concurrent and divergent validity.
Material and Methods. The study encompassed a sample of 90 participants distributed into 3 groups: Control (n = 30), MCI (n = 30) and Dementia (n = 30). In addition to ACE-III, Clinical Dementia Rating (CDR) and Montreal Cognitive Assessment (MoCA) were also used.
Results. The reliability of ACE-III was very good (α = 0.914). ACE-III significantly differentiated the 3 groups. The receiver operating characteristic (ROC) curves significantly favored ACE-III in comparison to another screening test – MoCA. ACE-III presented higher levels of sensitivity and specificity. Its total score correlated positively with the results on MoCA (ρ = 0.912; p < 0.001) and negatively with a depression scale (ρ = –0.505; p < 0.001).
Conclusion. The Portuguese version of ACE-III has very good reliability and high diagnostic capacity in the context of MCI and dementia. ACE-III also holds concurrent and divergent validity.

Key words

Alzheimer’s disease, screening test, neuropsychological assessment

References (20)

  1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006;367(9524):1747–1757.
  2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75.e2.
  3. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19(9):1159–1179.
  4. Petersen R, Stevens J, Ganguli M, et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133–1142.
  5. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2003;138(11):927–937.
  6. Sánchez LB, Muñoz MA, López MDB, et al. Estudio de validez del Test de las Fotos en el cribado de deterioro cognitivo en atención primaria. Revista Clínica de Medicina de Familia. 2007;2:57–62.
  7. Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s Cognitive Examination III in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2013;36(3–4):242–250.
  8. Matias-Guiu JA, de Bobadilla RF, Escudero G, et al. Validación de la versión española del test Addenbrooke’s Cognitive Examination III para el diagnóstico de demencia. Neurología. 2015;30(9):545–551.
  9. Qassem T, Khater MS, Emara T, et al. Normative data for healthy adult performance on the Egyptian-Arabic Addenbrooke’s Cognitive Examination III. Middle East Current Psychiatry. 2015;22(1):27–36.
  10. Machado A, Baeta E, Pimentel P, Peixoto B. Psychometric and normative indicators of the Portuguese version of the Addenbrooke’s Cognitive Examination III: Preliminary study on a sample of healthy subjects. Acta Neuropsychol. 2015;13(2):127–136.
  11. Velayudhan L, Seung-Ho R, Raczek M, et al. Review of brief cognitive tests for patients with suspected dementia. Int Psychogeriatr. 2014;26(8):1247–1262.
  12. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–194.
  13. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269.
  14. Freitas S, Simões MR, Martins C, Vilar M, Santana I. Estudos de adaptação do Montreal Cognitive Assessment (MoCA) para a população portuguesa. Avaliação Psicológica. 2010;9(3):345–357.
  15. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.
  16. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res. 1983;17(1):37–49.
  17. Frontier – NeuRA. https://www.neura.edu.au/frontier/research/test-downloads/. Accessed September 8, 2016.
  18. Santana I, Duro D, Lemos R, et al. Mini-Mental State Examination: Avaliação dos novos dados normativos no rastreio e diagnóstico do défice cognitivo. Acta Medica Portuguesa. 2016;29(4):240–248.
  19. Ritchie CW, Terrera GM, Quinn TJ. Dementia trials and dementia tribulations: Methodological and analytical challenges in dementia research. Alzheimers Res Ther. 2015;7(1):31.
  20. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: Possible implications for functional neuropathology. Br J Psychiatry. 2001;178:200–206.
© Wroclaw Medical University